Fingolimod

(Gilenya®)

Gilenya®

Drug updated on 9/14/2023

Dosage FormCapsule (oral; 0.25 mg, 0.5 mg)
Drug ClassSphingosine 1-phosphate receptor modulator
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older.

Product Monograph / Prescribing Information

Document TitleYearSource
Gilenya (fingolimod) Prescribing Information.2022Novartis Pharmaceuticals Corporation, East Hanover, NJ

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines